Noxopharm Limited (ASX:NOX) is an Australian clinical-stage drug development company focused on treating cancer with Veyonda®, its lead drug candidate.
Veyonda® is a dual-acting oncotoxic and immuno-oncology drug designed to enhance the effectiveness and safety of standard oncology treatments, i.e., chemotherapy, radiotherapy and immuno-oncology drugs. The drug acts by harnessing the body’s immune system to inflict damage oncancer cells in the body and has shown promise in treating a broad spectrum of cancers.
Noxopharm also has an active research and development (R&D) program for additional drug candidates and is the major shareholder of US biotechnology company Nyrada Inc. (ASX:NYR).
Market Reports /
by Rachael Jones -
4 years ago
08 Mar 2021 - The ASX took a dip in afternoon trade but still managed to close 0.4 per cent higher. At the closing bell the S&P/ASX 200 index closed 29 points higher, finish at 6,7…
Company News /
by Rachael Jones -
4 years ago
08 Mar 2021 - Drug development company Noxopharm (ASX:NOX) reports Veyonda has been approved to move into its second and final stage of the NOXCOVID-1 clinical trial.
Market Reports /
by Rachael Jones -
4 years ago
13 Jan 2021 - The ASX closed 8 points up, or 0.1% higher at 6,687. Shares in Premier Investments (ASX:PMV) hit an all-time high after reporting that they expect a significant uplif…
Company News /
by Rachael Jones -
4 years ago
13 Jan 2021 - Drug development company, Noxopharm (ASX:NOX) reports that the latest formal review by the NOXCOVID-1 Safety Steering Committee has cleared it to advance to the fifth…
Company Presentations /
by -
4 years ago
14 Dec 2020 - Noxopharm Limited (ASX:NOX) CEO and Managing Director Dr Graham Kelly gives an update on the company and its clinical trials.
Company News /
by Rachael Jones -
4 years ago
05 Nov 2020 - Clinical-stage drug development company Noxopharm Limited (ASX:NOX) has partnered with Hudson Institute of Medical Research and a collaboration with The Australian Na…
Interviews /
by Rachael Jones -
4 years ago
09 Oct 2020 - Noxopharm Limited (ASX:NOX) Chief Medical Officer Dr Gisela Mautner provides an update on the company's lead drug candidate Veyonda in its DARRT program and discusses…
Interviews /
by Rachael Jones -
4 years ago
23 Jul 2020 - Noxopharm Limited (ASX:NOX) Executive Chairman and CEO Dr Graham Kelly discusses important pre-clinical results for the company's programs.
Company Presentations /
by -
4 years ago
05 Jun 2020 - Noxopharm Limited (ASX:NOX) Executive Chairman and CEO Dr Graham Kelly and Chief Medical Officer Dr Gisela Mautner discuss ASCO 2020 Clinical data.
Interviews /
by Rachael Jones -
5 years ago
25 Feb 2020 - Noxopharm Limited (ASX:NOX) Chief Medical Officer, Dr Gisela Mautner, talks about results from the company's LuPIN trial in prostate cancer, evaluating its lead produ…
Company Presentations /
by -
5 years ago
20 Dec 2019 - Noxopharm Limited (ASX:NOX) CEO & Founder Dr Graham Kelly provides a summary and latest updates for the DAART Program. University of Wollongong's Head of School & Dea…
Company News /
by Katrina Bullock -
5 years ago
20 Dec 2019 - Clinical drug development company Noxopharm (ASX:NOX) has released DARRT-1 study clinical data which it says shows strong anti-cancer response in 47% of men with late…
Interviews /
by Rachael Jones -
5 years ago
03 Dec 2019 - Noxopharm Limited (ASX:NOX) Executive Chairman & CEO, Dr Graham Kelly, discusses clinical results from the company's Phase 1b clinical DARRT-1 trial for its lead prod…
Company Presentations /
by -
5 years ago
28 Nov 2019 - Noxopharm Limited (ASX:NOX) Executive Chairman and CEO, Dr Graham Kelly, Chief Medical Officer, Dr Gisela Mautner and Chief Commercial Officer, Alex Hunter provide an…
Market Reports /
by Rachael Jones -
5 years ago
16 Oct 2019 - It has been a positive day of trade for the ASX, closing 1.3% higher. Silverlake (ASX:SLR) and Nearmap (ASX:NEA) shot up today. Shares in the Afterpay Touch Group (AS…
Interviews /
by Katrina Bullock -
5 years ago
02 Oct 2019 - Noxopharm Limited (ASX:NOX) Founder and Executive Chairman, Dr Graham Kelly, discusses early results on the use of Noxopharm's lead drug candidate, Veyonda, for the t…
Market Reports /
by Rachael Jones -
5 years ago
24 Sep 2019 - The ASX failed to gain momentum after an early rise this morning and closed 0.01% lower. Treasury Wine Estates (ASX:TWE) shares dropped today after they released thei…
Interviews /
by Jessica Amir -
5 years ago
28 Aug 2019 - Noxopharm Limited (ASX:NOX) CEO Dr Greg van Wyk discusses the company's anti-prostate cancer drug Veyonda, its efficacy in prostate cancer treatment, the drug’s upsid…
Interviews /
by Rachael Jones -
5 years ago
09 Aug 2019 - Noxopharm Limited (ASX:NOX) Executive Chairman and Founder, Dr Graham Kelly, talks about progress with Veyonda, plans for a secondary listing in the US and key appoin…
Company News /
by Rachael Jones -
5 years ago
07 Jun 2019 - Noxopharm (ASX:NOX) has seen its majority-owned US subsidiary company, Nyrada receive a cash rebate of over $486,000 under the Australian Government’s R&D Tax Incenti…
Interviews /
by Jessica Amir -
5 years ago
02 May 2019 - Noxopharm Limited (ASX:NOX) CEO & CMO Dr Greg van Wyk talks about interim data at 24 weeks for the company's DARRT-1 clinical trial for prostate cancer.
